Lyka Labs Limited (BOM:500259)

India flag India · Delayed Price · Currency is INR
99.05
-0.50 (-0.50%)
At close: Aug 29, 2025
-0.50%
Market Cap3.60B
Revenue (ttm)1.38B
Net Income (ttm)73.97M
Shares Outn/a
EPS (ttm)2.06
PE Ratio48.69
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume151
Average Volume3,227
Open99.55
Previous Close99.55
Day's Range99.05 - 100.30
52-Week Range90.20 - 175.95
Betan/a
RSI38.88
Earnings DateOct 31, 2025

About Lyka Labs

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti... [Read more]

Industry Pharmaceutical Preparations
Founded 1976
Employees 499
Stock Exchange Bombay Stock Exchange
Ticker Symbol 500259
Full Company Profile

Financial Performance

Financial Statements

News

Lyka Labs shares fall 3% as Q1 net profit falls 20% YoY; Check earnings

Shares of Lyka Labs Ltd. fell by 2.82% to ₹112.90 on Thursday afternoon following the company’s Q1 FY26 earnings announcement, which revealed a 20% year-on-year drop in net profit. Q1 FY26 Highlights ...

4 weeks ago - Business Upturn

Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain

Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitm...

5 months ago - Business Upturn